LAE111 / Laekna Therap - LARVOL DELTA

Laikai Pharmaceuticals-B (02105) appeared at the 2023 SITC annual meeting with 2 achievements, and the international recognition of its innovation capabilities and configuration value were simultaneously improved. [Google translation] (Investing.com) - "On November 1, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, California, USA, Laika Medical-B (02105) announced the preclinical results of two independently developed new bispecific antibodies in the form of a poster. Data: LILRB1-B2 bispecific antibody (LAE111) that modulates T/NK/myeloid cell function, and TIGIT-PVRIG bispecific antibody (LAE113) that modulates T/NK cell function....When LAE113 is combined with PD-L1 monoclonal antibody (LAE005), it shows a synergistic effect in enhancing the secretion of IFN-γ by CD8+ T cells. In addition, when combined with antibodies that mediate ADCC effects, it significantly enhances the activity of NK cells and the effects of ADCC. LAE113 significantly inhibited tumor growth in the HuPBMC A375 xenograft model, outperforming clinical-stage control antibodies."

Preclinical • Oncology

Preclinical characterization of LAE111, a potent anti-LILRB1/LILRB2 antagonist bispecific antibody (SITC 2023) - "Lead bispecific antibodies were characterized in a panel of functional assays together with the competitor’s anti-LILRB1 mAb (15G8), anti-LILRB2 mAb (MK4830 and J19) and anti-LILRB1/LILRB2 dual mAb (NGM707), which are currently being tested in the clinical trials. Combination of LAE111 and PD1/PDL1 inhibitor markedly activated T cell response. These results support further development of LAE111 as a therapeutic for cancer."

Preclinical • Oncology • CD34 • LILRB1 • TNFA

Laekna, Inc. (2105.HK) Announces Interim Results 2023 (PRNewswire) - "We have advanced three PCC drug candidates from our internal discovery platform: LAE111, a LILRB1 and LILRB2 bispecific antibody; LAE113, a TIGIT-PVRIG bispecific antibody; and LAE112, a FGFR2b monoclonal antibody....EXPECTED UPCOMING MILESTONES: (i) Presenting LAE111/LILRB1-2 bispecific antibody as a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 38th annual meeting in San Diego, California, U.S., in November 2023; (ii) Presenting LAE113/TIGIT/PVRIG bispecific antibody as a poster presentation at the SITC 38th annual meeting in San Diego, California, U.S., in November 2023."

New molecule • Preclinical • Oncology